Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

被引：5
|
作者：
Tahara, Makoto
Kiyota, Naomi
Yokota, Tomoya
Hasegawa, Yasuhisa
Muro, Kei
Takahashi, Shunji
Onoe, Takuma
Homma, Akihiro
Taguchi, Jun
Suzuki, Masami
Minato, Koichi
Yane, Katsunari
Ueda, Shinya
Hara, Hiroki
Saijo, Ken
Yamanaka, Takeharu
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Kobe Univ Hosp, Div Med Oncol & Hematol, Dept Med, Kobe, Hyogo, Japan
[3] Grad Sch Med, Kobe, Hyogo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Caner Ctr, Nagoya, Aichi, Japan
[6] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[7] Ctr Canc Chemotherapy, Tokyo, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan
[10] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan
[11] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[12] Gunma Prefectural Canc Ctr, Ota, Japan
[13] Gunma Prefectural Canc Ctr, Div Resp Med, Ota Shi, Japan
[14] Nara Hosp Kinki Univ, Fac Med, Ikoma, Japan
[15] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[16] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[17] Tohoku Univ, Sendai, Miyagi, Japan
[18] Yokohama City Univ, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6026
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
    Tahara, M.
    Kiyota, N.
    Yokota, T.
    Hasegawa, Y.
    Muro, K.
    Takahashi, S.
    Onoe, T.
    Homma, A.
    Taguchi, J.
    Suzuki, M.
    Minato, K.
    Yane, K.
    Ueda, S.
    Hara, H.
    Saijo, K.
    Yamanaka, T.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1004 - 1009
  • [2] Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
    Ueda, Yuri
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Ito, Kazue
    Tahara, Makoto
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [4] Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Bhatia, Aarti K.
    Mehra, Ranee
    Khan, Saad A.
    Egleston, Brian L.
    Alpaugh, R. Katherine
    Lango, Miriam
    Ridge, John A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [6] Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
    Pivot, X
    Cals, L
    Cupissol, D
    Guardiola, E
    Tchiknavorian, X
    Guerrier, P
    Merad, L
    Wendling, JL
    Barnouin, L
    Savary, J
    Thyss, A
    Schneider, M
    ONCOLOGY, 2001, 60 (01) : 66 - 71
  • [7] Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
    Friesland, Signe
    Tsakonas, Georgios
    Kristensen, Claus
    Moren, Maria Herlestam Calero
    Haugen, Hedda
    Soderstrom, Karin
    Specht, Lena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [9] Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
    Tsakonas, Georgios
    Specht, Lena
    Kristensen, Claus Andrup
    Moreno, Maria Herlestam Calero
    Haugen Cange, Hedda
    Soderstrom, Karin
    Friesland, Signe
    CANCERS, 2020, 12 (11) : 1 - 11
  • [10] Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Bourhis, Jean
    Rivera, Fernando
    Mesia, Ricard
    Awada, Ahmad
    Geoffrois, Lionel
    Borel, Christian
    Humblet, Yves
    Lopez-Pousa, Antonio
    Hitt, Ricardo
    Vega Villegas, M. Eugenia
    Duck, Lionel
    Rosine, Dominique
    Amellal, Nadia
    Schueler, Armin
    Harstrick, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2866 - 2872
12345